Volume | 30,124 |
|
|||||
News | - | ||||||
Day High | 0.63 | Low High |
|||||
Day Low | 0.583566 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
VBI Vaccines Inc | VBIV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.63 | 0.583566 | 0.63 | 0.609 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
73 | 30,124 | $ 0.6266633 | $ 18,878 | - | 0.45 - 3.86 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:56:14 | 180 | $ 0.5915 | USD |
VBI Vaccines Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
14.45M | 23.69M | - | 1.08M | -113.3M | -4.78 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
VBI Vaccines News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VBIV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.62 | 0.652 | 0.55 | 0.5985256 | 443,014 | -0.0285 | -4.60% |
1 Month | 0.597 | 1.35 | 0.55 | 0.6873193 | 1,113,619 | -0.0055 | -0.92% |
3 Months | 0.62 | 1.35 | 0.53 | 0.6711064 | 471,108 | -0.0285 | -4.60% |
6 Months | 0.58 | 1.35 | 0.45 | 0.6573671 | 278,175 | 0.0115 | 1.98% |
1 Year | 3.67 | 3.86 | 0.45 | 1.68 | 507,288 | -3.08 | -83.88% |
3 Years | 81.30 | 129.30 | 0.45 | 55.57 | 1,599,987 | -80.71 | -99.27% |
5 Years | 61.20 | 217.20 | 0.45 | 74.62 | 3,531,151 | -60.61 | -99.03% |
VBI Vaccines Description
VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology. |